Insmed CEO’s Insider Trades Reveal Strategic Liquidity & Growth Focus
Insmed CEO’s insider trades reveal a disciplined 10‑b‑5‑1 strategy—buying low, selling high—to fund rare‑disease R&D, boost liquidity, and signal confidence for investors and payers alike.
4 minutes to read